Send to

Choose Destination
Diabetes Obes Metab. 2012 Feb;14(2):190-3. doi: 10.1111/j.1463-1326.2011.01495.x. Epub 2011 Oct 30.

Interleukin-15 treatment improves glucose homeostasis and insulin sensitivity in obese mice.

Author information

Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics and Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada.


The prevalence of metabolic diseases associated with obesity, such as type 2 diabetes, continues to rise along with obesity rates. Recently, obesity has been described as an inflammatory condition, suggesting a link between the dysregulation in proinflammatory cytokine production and the aetiology of these metabolic diseases. While known as an immunomodulatory cytokine, Interleukin-15 (IL-15) has been shown to have effects on adipose tissue and induce weight loss in diet-induced obese mice. As weight loss improves glucose homeostasis, the goal of this study was to determine whether IL-15 impacts glucose regulation in a mouse model of diet-induced obesity. Our data demonstrate that IL-15 treatment significantly improves insulin sensitivity and glucose and insulin responses to an oral glucose challenge compared to obese counterparts and/or lean controls. These results show that IL-15 may be a novel therapeutic target for the treatment of obesity and its associated abnormal glucose regulation.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center